Pearson SD - Search Results

1

Cost-Effectiveness of Nadofaragene Firadenovec and Pembrolizumab in Bacillus Calmette-Guérin Immunotherapy Unresponsive Non-Muscle Invasive Bladder Cancer.

Joshi M, Atlas SJ, Beinfeld M, Chapman RH, Rind DM, Pearson SD, Touchette DR. Joshi M, et al. Among authors: pearson sd. Value Health. 2023 Jun;26(6):823-832. doi: 10.1016/j.jval.2022.12.005. Epub 2022 Dec 16. Value Health. 2023. PMID: 36529422 Free article.

2

Cost-Effectiveness of Sacubitril-Valsartan in Patients With Heart Failure With Reduced Ejection Fraction.

Sandhu AT, Ollendorf DA, Chapman RH, Pearson SD, Heidenreich PA. Sandhu AT, et al. Among authors: pearson sd. Ann Intern Med. 2016 Nov 15;165(10):681-689. doi: 10.7326/M16-0057. Epub 2016 Aug 30. Ann Intern Med. 2016. PMID: 27571284

3

Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis.

Whittington MD, McQueen RB, Ollendorf DA, Tice JA, Chapman RH, Pearson SD, Campbell JD. Whittington MD, et al. Among authors: pearson sd. Ann Allergy Asthma Immunol. 2017 Feb;118(2):220-225. doi: 10.1016/j.anai.2016.10.028. Epub 2016 Dec 4. Ann Allergy Asthma Immunol. 2017. PMID: 27923549

4

Cost-Effectiveness of Sacubitril-Valsartan in Patients Who Have Heart Failure With Reduced Ejection Fraction.

Sandhu AT, Ollendorf DA, Chapman RH, Pearson SD, Heidenreich PA. Sandhu AT, et al. Among authors: pearson sd. Ann Intern Med. 2017 Apr 18;166(8):607-608. doi: 10.7326/L17-0044. Ann Intern Med. 2017. PMID: 28418550 No abstract available.

5

Cost-effectiveness of Drugs to Treat Relapsed/Refractory Multiple Myeloma in the United States.

Carlson JJ, Guzauskas GF, Chapman RH, Synnott PG, Liu S, Russo ET, Pearson SD, Brouwer ED, Ollendorf DA. Carlson JJ, et al. Among authors: pearson sd. J Manag Care Spec Pharm. 2018 Jan;24(1):29-38. doi: 10.18553/jmcp.2018.24.1.29. J Manag Care Spec Pharm. 2018. PMID: 29290170 Free PMC article.

6

The ICER Value Framework: Integrating Cost Effectiveness and Affordability in the Assessment of Health Care Value.

Pearson SD. Pearson SD. Value Health. 2018 Mar;21(3):258-265. doi: 10.1016/j.jval.2017.12.017. Value Health. 2018. PMID: 29566831 Free article. Review.

7

Evaluating and Valuing Drugs for Rare Conditions: No Easy Answers.

Ollendorf DA, Chapman RH, Pearson SD. Ollendorf DA, et al. Among authors: pearson sd. Value Health. 2018 May;21(5):547-552. doi: 10.1016/j.jval.2018.01.008. Value Health. 2018. PMID: 29753351 Free article.

8

The Authors Respond: Reframing the Value of Treatments for Relapsed Refractory Multiple Myeloma.

Carlson JJ, Guzauskas GF, Chapman RH, Synnott PG, Liu S, Russo ET, Pearson SD, Brouwer ED, Ollendorf DA. Carlson JJ, et al. Among authors: pearson sd. J Manag Care Spec Pharm. 2018 Jul;24(7):712-713. doi: 10.18553/jmcp.2018.24.7.712. J Manag Care Spec Pharm. 2018. PMID: 29952702 Free PMC article.

9

Long-term Survival and Value of Chimeric Antigen Receptor T-Cell Therapy for Pediatric Patients With Relapsed or Refractory Leukemia.

Whittington MD, McQueen RB, Ollendorf DA, Kumar VM, Chapman RH, Tice JA, Pearson SD, Campbell JD. Whittington MD, et al. Among authors: pearson sd. JAMA Pediatr. 2018 Dec 1;172(12):1161-1168. doi: 10.1001/jamapediatrics.2018.2530. JAMA Pediatr. 2018. PMID: 30304407 Free PMC article.

10

Cost-Effectiveness of Targeted Pharmacotherapy for Moderate to Severe Plaque Psoriasis.

Hendrix N, Ollendorf DA, Chapman RH, Loos A, Liu S, Kumar V, Linder JA, Pearson SD, Veenstra DL. Hendrix N, et al. Among authors: pearson sd. J Manag Care Spec Pharm. 2018 Dec;24(12):1210-1217. doi: 10.18553/jmcp.2018.24.12.1210. J Manag Care Spec Pharm. 2018. PMID: 30479197 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

221 results

Search Page

Filters